Technology
Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson’s Disease and Related Disorders
LEXINGTON, Mass., November 20, 2025--Valo Health announces collaboration with Merck KGaA, Darmstadt, Germany to discover and develop novel treatments for Parkinson’s and related disorders
About this update from Merck Kgaa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":334,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/db6e82204e80a4216c4ed654c0ebb417"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TvrAixhR0xULiAwv_Zj9og--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTkyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/db6e82204e80a4216c4ed654c0ebb417","width":334,"height":480}},"lazy":false},{"type":"text","content":"Partnership includes upfront and potential milestone payments totaling up to over 3 billion dollars","length":99,"tagName":"p","attribs":{}},{"type":"text","content":"LEXINGTON, Mass., November 20, 2025--(BUSINESS WIRE)--Valo Health, Inc. ("Valo"), a company pioneering the use of human data and AI to accelerate drug discovery and development, today announced a strategic collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to advance therapeutic discovery in Parkinson’s disease and related disorders. The partnership will leverage Valo’s AI-enabled human causal biology platform to identify and validate novel disease targets and its closed loop discovery platform to rapidly generate preclinical compounds. The partnership includes upfront and potential milestone payments totaling up to over 3 billion dollars, as well as royalties and R&D funding.","length":741,"tagName":"p"},{"type":"text","content":""Our research engine is focused on delivering meaningful medicines for patients with high unmet medical needs. Valo Health’s AI‑enabled platforms utilizing human data will help sharpen target selection and streamline drug discovery, enabling us to advance the most promising candidates faster," said Amy Kao, Global Head of Neurology & Immunology Research Unit at Merck KGaA, Darmstadt, Germany.","length":409,"tagName":"p"},{"type":"text","content":"Valo’s human causal biology platform harnesses unique access to more than 17 million de-identified patient records—some spanning 20 to 30 years—and biobank samples, combined with advanced AI, to uncover disease patterns and pinpoint potential targets for therapeutic intervention. In neurological conditions specifically, this robust human data has enabled Valo to identify distinct patient phenotypes across the disease spectrum, each...